Mucosally ingested and inhaled antigens are taken up by membranous or microfold cells (M cells)
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Membranous or microfold cells (M cells), which are located in the follicle-associated epithelium (FAE) of Peyer ' s patches (PPs) or nasopharynxassociated lymphoid tissue (NALT), play a pivotal role in the uptake of luminal antigens for induction of antigen-specifi c immune responses in both systemic and mucosal compartments ( 1 ) . Unlike their neighboring columnar epithelial cells, M cells are morphologically unique because they have irregular and short microvilli for the eff ective uptake of ingested or inhaled antigens from luminal sites in the aerodigestive tract; they subsequently transport the sampled antigen to professional antigen-presenting cells (e.g., dendritic cells) to initiate antigen sensitization ( 2 ) .
The mucosal immune system consists of two types of immunologically important sites, termed " inductive " and " eff ector " tissues, connected by the common mucosal immune system ( 3 ) . In general, antigen sensitization occurs at inductive sites, such as PPs, after antigen uptake by M cells. Induction of antigen-specifi c T helper 2 (Th2) cell -mediated IgA responses and Th1 celland CTL-dependent immune responses then occurs at eff ector sites such as the lamina propria ( 3 ) . However, our recent study demonstrated that the eff ector sites are also able to take up antigen, because antigen-sampling cells termed villous M cells are distributed in the intestinal villous epithelium ( 4 ) , and antigen-specifi c mucosal immune responses can be induced in PP-defi cient mice ( 5 ) .
Although mucosal vaccination is thought to be an ideal strategy for combating mucosal infectious diseases, only a few mucosal vaccines (e.g., polio vaccine and infl uenza vaccine) are but not of UEA-1 -negative epithelial cells. In addition, an electronmicroscopic analysis revealed that NKM 16 -2-4 specifi cally reacted with typical M cells, which have short and irregular microvilli and a pocket structure containing lymphocytes and/or monocytes ( Fig. 1 B ) . Furthermore, wholemount staining analysis revealed that NKM 16 -2-4 specifi cally reacted with villous M cells, in a manner similar to the reaction with PP-associated M cells ( Fig. 1 C ) .
M cells recognized by UEA-1 in mice are also present in the FAE of NALT, as they are in PPs, and act as antigensampling cells for the induction of mucosal immunity ( 15 ) , although our previous fi nding demonstrated that the mechanism of NALT organogenesis is distinct from that of PP organogenesis ( 16, 17 ) . Recently, it was reported that group A streptococcus infects its hosts through M cells ( 15 ) , meaning that M cells could be defi ned as a portal cell subset of mucosal infection in both the gastrointestinal and respiratory tracts. A subsequent immunohistochemical analysis of NALT tissue sections revealed that NKM 16 -2-4 specifi cally reacted with UEA-1 -positive M cells, but not UEA-1 -positive, morphologically typical goblet cells with secretory granules (Fig. S2 , available at http://www.jem.org/cgi/content/full/jem.20070607/DC1). These results further suggest the possibility of formulating an M cell -targeted nasal vaccine with NKM 16 -2-4 for protection against infectious diseases entering through the respiratory tract. Thus, in summary, the novel mAb NKM 16 -2-4 specifically reacted with all subsets of M cells, but not epithelial cells or goblet cells, located in PPs, NALT, and the intestinal villi; i.e., in both the gastrointestinal and respiratory tracts ( Table I ) .
Use of NKM 16 -2-4 to develop an M cell -targeted mucosal vaccine
Because it had been reported that the use of monoclonal antibodies to target injectable vaccine antigen to dendritic cells expressing endocytic receptor eff ectively initiated antigenspecifi c immunity ( 18, 19 ) , we next addressed the characteristics of NKM 16 -2-4 as a carrier vehicle of M cell -targeted mucosal vaccines. When we injected FITC-conjugated NKM 16 -2-4 or FITC-conjugated control rat IgG into intestinal loops containing PPs, FITC-conjugated NKM 16 -2-4 specifi cally attached to the apical surfaces of M cells in the dome regions of PPs within 10 min of inoculation, whereas FITCconjugated control rat IgG did not ( Fig. 2 A ) . Furthermore, FITC-conjugated NKM 16 -2-4 was taken into the cytoplasmic regions of M cells within 30 min ( Fig. 2 A ) and reached the basal membrane of the M cells within 4 h, indicating that NKM 16 -2-4 could likely be used as a carrier vehicle of orally administered vaccine antigen to M cells.
To directly confi rm that M cell -targeted mucosal vaccination with NKM 16 -2-4 is an eff ective strategy for inducing high-level, antigen-specifi c immune responses, tetanus toxoid (TT) was selected as a prototypical vaccine antigen, as TT has been extensively used in our previous experiments to elucidate the mechanism of the antigen-specifi c immune responses induced in both the mucosal and systemic compartments by mucosal immunization ( 20 ) . A chimeric complex of currently used in humans because they have lower effi cacy than the currently used injectable vaccines in inducing antigenspecifi c immune responses ( 6 ) . Because M cells possess the ability to take up luminal antigens, it is logical and attractive to develop a system of delivery of vaccine antigen to both PP-associated and villous M cells to create an eff ective mucosal vaccine ( 7 ) . In fact, Ulex europaeus agglutinin-1 (UEA-1) -conjugated ( 8, 9 ) or 1 protein -conjugated nasal vaccination ( 10, 11 ) induce not only strong antigen-specifi c plasma IgG and mucosal IgA responses but also CTL immunity, because UEA-1 specifi c for ␣ (1,2) fucose specifi cally reacts with murine PP -associated and villous M cells ( 4, 12 ) , and 1 protein derived from reovirus specifi cally binds to a carbohydrate structure containing ␣ (2,3)-linked sialic acid on the membranes of M cells ( 13 ) . However, because UEA-1 also reacts strongly with goblet cells and the mucus layer covering the intestinal epithelium ( 14 ) , there have been no eff ective oral vaccines with UEA-1 as an M cell -targeting vehicle. To overcome this obstacle, we established an M cell -specifi c mAb and developed a novel strategy for oral vaccination with high effi cacy.
RESULTS AND DISCUSSION Establishment of an M cell -specifi c monoclonal antibody (NKM 16 -2-4)
To characterize the antigen-sampling M cells for development of an eff ective M cell -targeted mucosal vaccine, SpragueDawley (SD) rats were immunized 4 times at 2-wk intervals with highly purifi ed ( > 95%) UEA-1 -positive cells isolated from murine PPs to establish an M cell -specifi c mAb. A total of 1,000 hybridomas were generated and screened by immunohistochemical analysis of intestinal tissue sections containing PPs. On the basis of the initial screening, one clone (NKM 16 -2-4; rat IgG2c), which possessed specifi city to M cells located in the FAE of PPs ( Fig. 1 A ) , was selected. Half of the hybridomas showed no specifi city to tissue sections; ‫ف‬ 40% of them showed strong reactivity to goblet cells and their secretions; and 10% showed reactivity to the microvilli in all parts of the intestinal epithelium, including M cells and neighboring columnar epithelial cells (unpublished data). These initial screening data indicated that the goblet cells contained in the immunized UEA-1 -positive fraction, and their secretions, were vastly immunodominant compared with M cells. However, importantly, NKM 16 -2-4 possessed no reactivity to UEA-1 -positive goblet cells located in the intestinal villi ( Fig. 1 A ) , indicating that NKM 16 -2-4 is a novel mAb possessing high specifi city to murine M cells. This is unlike the already known murine M cell -specifi c lectin UEA-1, which also reacts with goblet cells and their secretions ( 14 ) . In addition, NKM 16 -2-4 reacted very strongly with the apical surfaces of the M cells ( Fig. 1 A ) , rather than the cytoplasm, suggesting that it might be able to be used as a carrier vehicle of M cell -targeted mucosal vaccine. In support of these results, fl ow cytometric and immuno-and lectin-cytochemical analyses demonstrated that NKM 16 -2-4 specifi cally reacted with the surfaces of isolated UEA-1 -positive M cells ( 
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IgG or 50 g noncoupled TT induced, at best, very low TTspecifi c immune responses ( Fig. 2 B ). In addition, the level of the TT-specifi c immune response induced by TT-conjugated UEA-1 was lower than that induced by TT-conjugated NKM 16 -2-4. These data suggest that an M cell -targeted mucosal vaccine with UEA-1 might be insuffi cient for antigen delivery to M cells, because the UEA-1 -based vaccine is trapped by goblet cells and their secreting mucus, as well as by M cells. Furthermore, 10 times more noncoupled TT (500 g) induced a small TT-specifi c immune response compared with TTconjugated NKM 16 -2-4 containing 50 g TT ( Fig. 2 B ) , perhaps because of the low effi cacy of antigen delivery to M cells for the induction of antigen-specifi c immune responses. Although the levels of the antigen-specifi c antibody responses induced here by immunization with noncoupled TT and CT tended to TT conjugated with NKM 16 -2-4 or control rat IgG (in total, each 200 g contained 50 g TT per mouse) was prepared by using avidin -biotin complexes (see Materials and methods). The prepared complexes consisted of TT and NKM 16 -2-4 or control rat IgG; these complexes, or noncoupled TT, were orally administered to mice, together with the mucosal adjuvant cholera toxin (CT). In addition, it has been reported that M cell -targeted mucosal vaccine with UEA-1 is eff ective in inducing antigen-specifi c humoral and cellular immunity when administered via the nasal route ( 8, 9 ) ; therefore, we prepared an orally administered TT-conjugated UEA-1 as a control for the effi cacy of the NKM 16 -2-4 -based M cell -targeted mucosal vaccines. As expected, brisk TT-specifi c serum IgG and mucosal IgA responses were induced in mice immunized with TTconjugated NKM 16 -2-4, whereas TT-conjugated control rat be lower than those in a previous study ( 20 ) , this discrepancy might have been caused by diff erences in the mouse haplotype or the sources of TT and CT. Despite the discrepancy, our current fi ndings emphasize the eff ectiveness of the newly established NKM 16 -2-4 for the targeting of vaccine antigen to M cells to induce antigen-specifi c immune responses.
Moreover, when mice were orally immunized with botulinum toxoid (BT) conjugated with NKM 16 -2-4 or control rat IgG (in total, each 200 g contained 50 g BT per mouse) in the presence of CT, brisk botulinum toxin -specifi c serum IgG and fecal IgA responses were induced in mice immunized with BT-conjugated NKM 16 -2-4, but not in those immunized with BT-conjugated control rat IgG ( Fig. 2 C ) . In addition, the mice immunized with BT-conjugated NKM 16 -2-4 survived after challenge with 200 ng (10,000 × LD 50 ) of botulinum toxin, whereas the mice immunized with BTconjugated control rat IgG died within 3 h ( Fig. 2 D ) . These data strongly indicate that the M cell-targeted mucosal vaccine with NKM 16 -2-4 can eff ectively induce protective immunity with the minimum dose of vaccine antigen.
To confi rm the mechanism by which the NKM 16 -2-4 -based M cell -targeted mucosal vaccine induces brisk antigen-specifi c immune responses in the systemic and mucosal compartments, and its universality, OVA was then chosen as a prototype antigen with low antigenicity. An immunocytochemical analysis revealed that Alexa Fluor 647 -labeled OVA conjugated with NKM 16 -2-4 and FITC-conjugated avidin specifi cally reacted with UEA-1 -positive isolated M cells in vitro ( Fig. 3 A ) , and intestinal loop assay clearly demonstrated that it specifi cally attached to the apical surfaces of M cells and was subsequently taken up into the cytoplasmic regions of M cells in vivo ( Fig. 3 B ) . Furthermore, brisk increases in the levels of OVA-specifi c serum IgG were induced in mice immunized with only 200 g OVAconjugated NKM 16 -2-4 (containing 50 g OVA), but not with the same amount of OVA-conjugated control rat IgG ( Fig. 3 C ) . Our previous study showed that amounts of OVA as high as 1 mg were required to induce OVA-specifi c immune responses ( 5 ); now, oral immunization with even small amounts of poorly immunogenic antigens (e.g., OVA) is possible by using the M cell -targeting concept with NKM 16 -2-4.
We could not directly compare the effi cacy of NKM 16 -2-4 -based mucosal vaccine with those of already pub- 

Identifi cation of antigens recognized by NKM 16 -2-4
In attempts to elucidate the antigen-sampling mechanism of M cells for the induction of antigen-specifi c immune responses, a major drawback has been the lack of knowledge of the specifi c genes and the corresponding molecules expressed by M cells. In addition, no information regarding which murine M cell -specifi c glycoproteins are recognized by UEA-1 is currently available, although UEA-1 is used extensively as a specifi c marker of M cells in mice. Therefore, we tried to identify the membrane antigen recognized by NKM 16 -2-4 by using a proteomics approach with liquid chromatographytandem mass spectrometry (LC-MS/MS) after immunoprecipitation of an M cell lysate with NKM 16 -2-4. 4 major bands (3 bands > 250 kD and 1 band of ‫ف‬ 150 kD) were precipitated by NKM 16 -2-4 ( Fig. 4 A ) , and these were identifi ed by LC-MS/MS as maltase glucoamylase (top three bands) and alanyl (membrane) aminopeptidase (bottom band). These two molecules, which have been reported as intestinal enzymes of 410, 275, and 260 kD ( 21 ) , and 150 kD, respectively, ( 22 ) under denatured conditions, are distributed at the brush borders of epithelial cells for the fi nal digestion of dietary nutrients ( 21, 22 ) . Because they were not homologous specifi city for villous M cells. However, our strategy for using NKM 16 -2-4 as an M cell -targeting vehicle might be superior, because NKM 16 -2-4 possesses specifi city for both villous M cells and PP-associated M cells. In support of our hypothesis, our previous data showed that villous M cells are capable of taking up orally administered antigens for the induction of PP-independent, antigen-specifi c immune responses ( 4 ). However, it should be noted that TT-or OVA-specifi c immune responses were not eff ectively induced without the presence of the mucosal adjuvant CT, even if the antigen was targeted to M cells by using NKM 16 -2-4. This fi nding could be explained by the observation that the gastrointestinal immune system generally operates via a sophisticated mucosal regulatory network to avoid unnecessary hyperimmune responses to the numerous orally encountered antigens in the harsh environment of the intestinal tract ( 3 ). Therefore, it is essential to use the mucosal adjuvant, which temporarily breaks the mucosal regulatory network system, to activate gastrointestinal immunity. In practical terms, further studies are needed to develop a safe mucosal adjuvant and take advantage of M cell -targeted mucosal vaccines with NKM 16 -2-4. On the basis of our hypothesis, we transfected Chinese hamster ovary (CHO) cells with the genes encoding murine fucosyl transferase 1 (mFUT1) or mFUT2, which have been identifi ed as ␣ (1,2) fucose transfer enzymes ( 23 ) . A fl ow cytometric analysis revealed that both NKM 16 -2-4 and UEA-1 specifi cally reacted with CHO cells expressing mFUT1 or mFUT2, but neither NKM 16 -2-4 nor UEA-1 showed specifi city for original or empty vector -transfected CHO cells ( Fig.  4 C ) . In addition, a blocking analysis showed that pretreatment of NKM 16 -2-4 with ␣ -l -fucose did not completely abolish reactivity to mFUT1-or mFUT2-expressing transfectants, although UEA-1 reactivity to these transfectants was dramatically decreased (Fig. S4 , available at http://www.jem.org/cgi/ content/full/jem.20070607/DC1), indicating that the epitope recognized by NKM 16 -2-4 is an mFUT1-or mFUT2-mediated carbohydrate complex containing ␣ (1,2) fucose that is diff erent from the UEA-1 -reactive portion of ␣ (1,2) fucose.
Because immunohistochemical analysis demonstrated that UEA-1, but not NKM 16 -2-4, recognized goblet cells in the intestinal villi ( Fig. 1 A ) , we turned to examining the diff erences in recognition patterns between NKM 16 -2-4 and UEA-1 by using a mutant line of CHO cells to elucidate the importance of the glycosylation of M cells and goblet cells in the mucosal immune system. When the mFUT1 or mFUT2 gene was introduced into a mutant line of CHO cells (Lec2) with an inactivated CMP-sialic acid transporter ( 24 ) , the reactivity of NKM 16 -2-4, but not of UEA-1, was higher in these transfectants than in the mFUT1-or mFUT2-expressing original CHO cells; however, mFUT1-or mFUT2-expressing Lec1 cells with inactivated GlcNAc transferase I (i.e., a lack of N -glycans) ( 25 ) or Lec8 cells with inactivated UDP-galactose transporter ( 26 ) were not recognized at all by NKM 16 -2-4. On the other hand, we observed very low reactivity of UEA-1 to mFUT1-or mFUT2-expressing Lec8 cells, although mFUT1-or mFUT2-expressing Lec1 cells were not recognized by UEA-1. This is because UEA-1 might recognize ␣ (1,2) fucose, which is linked to very low levels of galactose on N glycans in mFUT1-or mFUT2-expressing Lec8 cells because it has been reported that Lec8 cells retain 10 -20% of their galactosylation ( 26 ) , and no information is currently available on whether ␣ (1,2) fucose links to anything other than galactose. These data suggest that sialic acid might be useful in distinguishing the reactivity of NKM 16 -2-4, but not UEA-1 to galactose-binding ␣ (1,2) fucose on N -glycans, although the reactivity to ␣ (1,2) fucose regulated by O -glycans remains unclear. Thus, our initial immunohistochemical analyses demonstrated that the specifi city of NKM 16 -2-4 to UEA-1 -positive M cells, but not UEA-1 -positive goblet cells, is attributable to the existence of abundant sialic acids neighboring the ␣ (1,2) fucose -containing carbohydrate moiety on goblet cells, but not on M cells. With the exception of their expression patterns at the tissue level, there is currently little reliable information available on the glycobiological and molecular biological differences between mFUT1 and mFUT2 as ␣ (1,2) fucosyltransferases ( 23 ) . Therefore, further studies, especially in terms of in situ expression patterns at a cellular level at inductive with each other, and subsequent in situ hybridization analysis demonstrated that their mRNAs were ubiquitously and abundantly expressed in the intestinal epithelium, including in M cells (Fig. S3 , available at http://www.jem.org/cgi/content/ full/jem.20070607/DC1), we hypothesized that NKM 16 -2-4 possesses specifi city for the M cell -specifi c carbohydrate moiety containing ␣ (1,2) fucose, as the precipitated antigens were commonly recognized by UEA-1 ( Fig. 4 B ) . 
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was incubated with the same volume of avidin (1 mg/ml; Sigma-Aldrich). The complexes were then incubated with twice the volume of biotinylated NKM 16 -2-4, biotinylated control rat IgG (Sigma-Aldrich), or biotinylated UEA-1 (Vector Laboratories; each 1 mg/ml). Mice were orally immunized with the complexes (in total, each 200 g contained 50 g TT or BT per mouse), noncoupled TT (50 or 500 g per mouse), or PBS alone 3 times (once a week), together with 10 g CT (List Biological Laboratories) as a mucosal adjuvant. 7 d after the fi nal immunization, serum and fecal extracts were collected and analyzed for TT-or type A botulinum toxin -specifi c serum IgG and fecal IgA responses by ELISA, as previously described ( 5, 27 ) . To examine the protective immunity, the mice were challenged via the i.p. route with 200 ng type A botulinum toxin (10,000 × LD 50 i.p.) diluted in 100 l of 0.2% gelatin/PBS ( 27 ) . To confi rm the universality of M celltargeted mucosal vaccine with NKM 16 -2-4, OVA (Sigma-Aldrich) was conjugated with NKM 16 -2-4 or control rat IgG and orally immunized together with 10 g CT. In addition, intestinal loop assay was performed by using M cell -targeted OVA composed of Alexa Fluor 647-conjugated OVA (Invitrogen), FITC-conjugated avidin (Sigma-Aldrich), and NKM 16 -2-4 or control rat IgG. Conjugation of NKM 16 -2-4 or control rat IgG and the protein antigen was confi rmed by sandwich ELISA (unpublished data).
Analysis of antigen recognized by NKM 16 -2-4.
To identify the antigen recognized by NKM 16 -2-4, we performed an immunoprecipitation assay with NKM 16 -2-4 followed by an LC-MS/MS analysis. In brief, a lysate of M cells was incubated with 10 g/ml NKM 16 -2-4 or an isotype control antibody (rat IgG2c; BD Biosciences) followed by protein G -Sepharose (GE Healthcare). Immune complexes were analyzed by SDS-PAGE and Western or lectin blot with 5 g/ml biotinylated NKM 16 -2-4, 5 g/ml biotinylated isotype control antibody (biotin-conjugated rat IgG2c; BD Biosciences), or 5 g/ml biotinylated UEA-1 (Vector Laboratories) and ABC -AP complex (Vector Laboratories). To identify the precipitated antigen, LC-MS/MS analysis was performed after digestion with 50 nM trypsin gold (Promega). 2 d after transfection, the cells were stained with 500 ng/ml Alexa Fluor 647 -conjugated NKM 16 -2-4 and 500 ng/ml PE-conjugated UEA-1, followed by the application of 10 l/test VIA-PROVE (BD Biosciences). They were then analyzed by fl ow cytometry with FACSCalibur (Becton Dickinson). For blocking analysis, 500 ng/ml Alexa Fluor 647 -conjugated NKM 16 -2-4 or 500 ng/ml PE-conjugated UEA-1 was fi rst pretreated with 0.5 M ␣ -Lfucose (Wako).
Data analysis. Data are expressed as the mean ± the SD. All analyses for statistically signifi cant diff erences were performed by Tukey ' s t test, with P < 0.01 considered signifi cant (denoted in the fi gures with an asterisk).
Online supplemental material. Fig. S1 shows the specifi city of NKM 16 -2-4 to isolated UEA-1 -positive M cells. Fig. S2 shows that NKM 16 -2-4 specifi cally reacts with M cells in NALT, similar to its reaction with PPassociated M cells. Fig. S3 shows the expression of maltase glucoamylase and alanyl aminopeptidase mRNAs in PPs. sites, such as in PPs, are needed to elucidate the role of the carbohydrate moiety containing ␣ (1,2) fucose in the mucosal immune system. In summary, we established a novel M cell -specifi c mAb (NKM 16 -2-4; rat IgG2c) that selectively recognizes M cells, but not goblet cells or epithelial cells, and we characterized the M cell -specifi c carbohydrate moiety containing ␣ (1,2) fucose. Our strategy for M cell -targeted vaccination with NKM 16 -2-4 is attractive for the development of mucosal vaccines.
MATERIALS AND METHODS
Animals.
Female BALB/c mice, Crlj: CD1-Foxn1 nu mice, and SD rats between 6 and 8 wk old were obtained from CREA and Charles River Laboratories. All of them were maintained in the experimental animal facility at the Institute of Medical Science, the University of Tokyo, and experiments were performed according to the guidelines provided by the Animal Care and Use Committee of the University of Tokyo.
Establishment of an M cell -specifi c mAb. The M cell -enriched fraction was prepared from murine PPs as previously described, with some modifi cation, by using UEA-1 ( 4 ). In brief, cells isolated from murine PPs were fi xed in 4% paraformaldehyde (Wako) and stained with 500 ng/ml PE-conjugated UEA-1 (Biogenesis). UEA-1 -positive cells were sorted by a FACSAria cell sorter (Becton Dickinson) and injected into the footpads of SD rats (10 6 cells/ rat) 4 times at 2-wk intervals, with TiterMax Gold (TiterMax) as an adjuvant. 4 d after the fi nal immunization, lymphocytes isolated from the spleen and inguinal lymph nodes of the immunized rats were fused with P3X63-AG8.653 myeloma cells (CRL-1580; American Type Culture Collection) in the presence of 50% (wt/vol) polyethylene glycol 1500 (Roche). Established hybridomas were injected into Crlj: CD1 -Foxn1 nu mice, and mAbs were then purifi ed from ascitic fl uids by using protein G -Sepharose (GE Healthcare) and labeled with EZ-Link Sulfo-NHS-LC-biotin (Thermo Fisher Scientifi c), FITC (Sigma-Aldrich), or Alexa Fluor 647 (Invitrogen).
Immunohistochemical analysis. One monoclonal antibody (NKM 16 -2-4; rat IgG2c) was selected on the basis of the initial screening and its specifi city to M cells determined by immunohistochemical and whole-mount staining analyses, as described previously, with some modifi cation ( 4 ). In brief, after a blocking step with 1% BSA, 7-m fi xed frozen sections or fi xed tissues containing PPs were stained with 5 g/ml FITC-conjugated NKM 16 -2-4 or FITC-conjugated isotype control (FITC-conjugated rat IgG2c; MBL International) and 1 g/ml tetrarhodamine isothiocyanate -conjugated UEA-1 (Vector Laboratories). The sections were then counterstained with 400 ng/ml DAPI (Sigma-Aldrich) for histochemical analysis and analyzed under a confocal laser-scanning microscope (TCS SP2; Leica). For electronmicroscopic analysis, ultrathin sections (100 nm) were incubated with 1 g/ml purifi ed NKM 16 -2-4 after blocking with 1% BSA, followed by 18-nm gold particle -conjugated goat anti -rat IgG (Jackson Immunoresearch Laboratories) diluted 1:10. Finally, the sections were stained with 4% uranyl acetate and analyzed under a transmission electron microscope (JEM100S; JEOL).
Uptake of NKM 16 -2-4 by M cells. After the mice were anesthetized with 2 mg ketamine (Sigma-Aldrich), we injected 100 g of FITC-conjugated NKM 16 -2-4 or FITC-conjugated control rat IgG (Sigma-Aldrich) into intestinal loops containing PPs, in accordance with our previous study ( 4 ) . The mice were killed 10 or 30 min, or 4 h, after the inoculation, and frozen sections (7 m) of intestinal loop were prepared and analyzed under a confocal laser-scanning microscope after counterstaining with DAPI.
M cell -targeted vaccination. TT (provided by the Research Foundation for Microbial Diseases, Osaka University, Osaka, Japan) and type A BT (prepared according to a previous study; reference [ 27 ) ]) were fi rst treated with EZ-Link Sulfo-NHS-LC-biotin. Next, biotinylated TT or BT at 1 mg/ml
